Get started
Maha Energy AB - bullish viewOMXSTO:MAHA_A Maha Energy AB is an undervalued Swedish oil stock with production in Brazil. Extremely good netback in excess of $ 40 per. barrel. The company has suffered from being downgraded in 2019 because a separator gauge for measuring the gas to be assured was incorrect and a new one had to be obtained from abroad and verified by authorities, which caused production to decline at the end of 2019 when they no longer had to flare the gas and handling the gas was not possible due to this gas meter. The company now guides with approx. 100% more oil for 2020 than they ended 2019 with. When the company does this the price should be above ATH. RSI is in a rising trend and the corresponding price is bottoming. RSI, trend and volume indicate that we will move up to price 23-25 in the coming time and can the company deliver the goods in the form of the guided oil volume we must towards ATH.
OMXSTO:MAHA_ALong
by Miniforvalter
Why I am shorting Sandvik [SAND] | Technical AnalysisFor you who would like to check the company out more in dept: www.home.sandvik §1 Fundamental blah blah §2 Position and forecast §3 Technical summary §1 Fundamental blah blah Sandvik is a Swedish company which is well diversified troughout the mechanical industry. They make things like: Ceramic metal cutting tools and tool holders Mining equipment CNC machines (computer controlled metal working machines - Computer numerical controll) Special alloys Induction heating elements (for heating special tool holders which require heating to change tools, hard to explain) I think sandvik is a great company, but at the price it's at today, I don't think big investors are going to look at buying more stocks, not only because of market fear (which there is undoubtedly a lot of)... But I also think most of the big investors are looking to exit their positions around this mark as it was the last high, and a very significant one at that. §2 Position and forecast My current position is short from - price is currently so it hasn't really moved since i put my short on. I think there is quite a big possibility that price will drop within the next week, if not it will likely consolidate until the market gains bullish momentum again. §3 Technical summary Bearish divergence on the RSI Price is at significant resistance Price met trend line resistance and resistance at and fell to previous support, until price breaks 182.50 level my stance will be bearish.
OMXSTO:SANDShort
by DonBboy
Triangle formation near apex. Break up gives buy signalBonesupport reported some very promising results in the latest report, but the market has not yet, in my opinion, realised its value. It actually gave no effect at all on the stock. ABG sundal Collier recently raised the target price to 53kr from 30kr. ABG Sundal Collier höjer riktkursen för Bonesupport till 53 kronor från 30 kronor. Rekommendationen köp upprepas. Det framgår av en analys. Carnegie is acting as sell block at the moment but when they loosen their sell pressure, the revaluation can begin. A triangle formation with a raising introduction is getting closer to its apex and if the stock breaks the triangle roof, a price of 46kr is justified. Overall there is both technical and fundamental support at this level (30kr-35kr) and is in my opinion undervalued. --- This is not a recommendation, but rather my speculations and personal thoughts. You should always make your own analysis before buying any stock. ---
OMXSTO:BONEXLong
by EXLUSIVOO
Xbrane moving out of DowntrendXbrane Biopharma AB is a biotechnology company which develops and manufactures biosimilars. Xbrane has a patented protein production platform and world-leading expertise within biosimilar development. Xbrane’s headquarter is located in Solna, just outside of Stockholm, and the company has research and development facilities in Sweden and in Italy. Biosimilars are approved pharmaceuticals that are similar to a biological reference product in terms of quality, safety and efficacy. They are approved in highly regulated markets such as the EU and the US. Biosimilars are so far typically launched with a 20-40% discount vs. the reference biological drug improving significantly the accessibility of the treatments and generating massive cost savings for private and public payors. Xlucane - Lucentis® - Phase 3 - Global annual sales € 3.2 billion phase III trial was initiated Q1 2019 with primary aim to evaluate comparative efficacy in terms of change in visual acuity 8 weeks after initiation of treatment. Xbrane has acceptance for the study design from both EMA and FDA. The target is to launch the product upon patent expiration in Europe beginning of 2022. Preclinical drugs Spherotide - Decapeptyl® Xcimzane - Cimzia® - Global annual sales € 1.4 billion Xoncane - Oncaspar® Xbrane has entered into a co-development agreement for Xlucane with the German generic/biosimilar company STADA. Under the agreement Xbrane is responsible for development of the product and STADA for sales and marketing. Development expenses and profits generated from sales of the product are shared 50/50.
OMXSTO:XBRANELong
by Charlestrad3r
L/S Swedish Equities Pairs TradeConsumer Defensive / Consumer Cyclical 30/12/2019 Close Long: ESSITY_B Current Price SEK: 301.80 Short: WESC_AB Current Price SEK: 0.0046 ESSITY / WESC spread Entry Range: 65608.70 ESSITY / WESC spread Hard Stop: 59076.70 (10%) ESSITY / WESC spread Soft Target: 85374.00 (30%) BETA hedge For every SEK 1.00 Long of ESSITY_B SEK 9.00 Short of WESC_AB *Build you position in two stages enter with 50% of desired exposure. *+add too the position on a breakout or at the soft target. *Hedge your currency exposure, unless you have a view on SEK. *HIGH RISK trade. Essity: Consumer Defensive (Manufacture Tissues, Toilet paper & other hygiene products) Strong fundamentals, very defensive and predictable earnings with consistent global demand, outperformed all of its competitors in 2019. *Market Cap = 212B *EPS = 14.10 ESSITY_B Consensus Jan 2020 =F1 Jan 2021 =F2 F1 P/E: 20.10x F2 P/E: 17.60x F1 Earnings Growth: 22.38% F2 Earnings Growth: 6.70% F1 Sales Growth: 2.70% F2 Sales Growth: 3.00% F1 PEG: 0.89 F2 PEG: 2.62 Risk: Reflation of the global economy, and solid resolution of political tensions. And therefore a full risk on scenario and defensive stock underperformance. Wesc: Consumer Cyclical (Trades Apparel & related products, under it brand name WESC) Weak fundamentals, very cyclical and “polluting” as it’s fast low quality fashion. Loss making. In desperate need of a turn around, I feel the business will not attract new talent (As the brand is notoriously NOT cool for millennials and gen z) and isn’t worth turning around as a brand, also no analyst and very hard to find relevant financial information in for the company. *Market cap = 22M *EPS = -0.0150 Risk: Merger, acquisition or turnaround. Otherwis I’d be happy to keep this position on for the foreseeable future. *KEEP YOUR POSITION SIZE SMALL* This is a risky pairs trade as WESC could get bought out, or turned around and go to infinity, but I’m betting against that. LONG High quality Swedish Consumer Staple. SHORT Low quality Swedish Consumer Cyclical.
OMXSTO:ESSITY_B
by Impreza